Study Testing Convalescent Plasma vs Best Supportive Care

Study Overview
=================
Brief Summary
-----------------
Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.

Detailed Description
-----------------
Experience from prior outbreaks with other coronaviruses, such as SARS-CoV-1 shows that convalescent plasma contains neutralizing antibodies to the relevant virus. In the case of SARS-CoV-2, the anticipated mechanism of action by which passive antibody therapy would mediate protection is viral neutralization. The only antibody type that is currently available for immediate use is that found in human convalescent plasma. As more individuals contract COVID-19 and recover, the number of potential donors will continue to increase. The investigators seek to treat participants who are sick enough to warrant hospitalization prior to the onset of overwhelming disease.

Official Title
-----------------
Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19

Conditions
-----------------
Pneumonia, Interstitial

Intervention / Treatment
-----------------
* Biological: high-titer anti-Sars-CoV-2 plasma
* Other: oxygen therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Donor: 18 years or older must have been hospitalized w/COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing but are now PCR negative by 2 nasopharyngeal testing females of child-bearing potential must have a negative serum pregnancy test subject and/or LAR willing to provide informed consent patient agrees to storage of specimens for future testing Inclusion Criteria Recipient: 18 years or older must have been hospitalized w/COVID-19 respiratory symptoms within 3 to 7 days from the beginning of illness subject and/or LAR willing to provide informed consent patient agrees to storage of specimens for future testing Exclusion Criteria: 18 years or older receipt of pooled immunoglobulin in past 30 days contraindication to transfusion or history of prior reactions to transfusion blood products females who are identified as donors must not be pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: convalescent plasma<br>This arm will receive convalescent plasma | Biological: high-titer anti-Sars-CoV-2 plasma<br>* Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer >1:64 vs best supportive care<br>|
| Placebo Comparator: best supportive care<br>Oxygen therapy | Other: oxygen therapy<br>* oxygen therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction in oxygen and ventilation support | reduction in oxygen and ventilation support | through study completion, an average of 4 weeks |